InvestorsHub Logo
Followers 21
Posts 4747
Boards Moderated 0
Alias Born 06/24/2006

Re: None

Tuesday, 06/12/2007 10:29:23 AM

Tuesday, June 12, 2007 10:29:23 AM

Post# of 3757
IDIX.. apparently BS was upset on the ITT basis results @ 12 weeks.

the fact that there were no drug drug interaction and response w/ NM283 is dose related (and 200 mg was used here) says there is room for improvement...

most importantly the triple beat the SoC @ all points thru the trial

obviously there is a long way to go... but the pathway for NM283 is clearer today. AND IMO upgrades will follow...



The creation of a thousand forests is in one acorn.